Eli Lilly releases cheaper, single-use vials of weight loss drug

Pharmaceutical company Eli Lilly announced it will begin selling single-use vials of Zepbound (tirzepatide), a popular weight loss drug, allowing patients to access the medication at a lower price point. 

The move will make Zepbound easier to access and increase supply, as it is cheaper than brand-named pens typically used to administer the drug. The single-use vials are easily administered via injection.

However, the company said it will exclusively distribute the new Zepbound through its telehealth platform, LillyDirect, which delivers drugs through the mail. The price point is expected to attract patients paying out of pocket, as many insurance plans will not cover weight loss medications.

"Distributing the vials via this channel ensures patients and providers can trust they are receiving genuine Lilly medicine, building on the company's efforts to help protect the public from the dangers posed by the proliferation of counterfeit, fake, unsafe or untested knock-offs of Lilly's medications," the company said in a statement

For now, vials cost around $100 for the standard 2.5 mg dose, with 5 mg vials costing $137 a pop. The company said this is less than half the price of similar medications. 

Zepbound is approved for use by adults with obesity, or those who are overweight and also have weight-related medical problems, such as diabetes. It’s prescribed for use as part of a larger diet and weight loss program.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

If passed, this bill would help clinician-led clinical registries explore Medicare data for research purposes. The Society of Thoracic Surgeons and American College of Cardiology both shared public support for the bipartisan legislation. 

Cardiologists and other physicians may soon need to provide much more information when ordering remote patient monitoring for Medicare patients.

Trimed Popup
Trimed Popup